Document Detail


Successful salvage chemotherapy for isolated central nervous system (CNS) relapse in Burkitt lymphoma: monocentric experience of 3 pediatric patients.
MedLine Citation:
PMID:  19131795     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Short-term intensive chemotherapy regimens have substantially improved the prognosis of pediatric patients with Burkitt lymphoma (BL), which now has an excellent overall outcome. However, central nervous system (CNS) involvement at diagnosis remains a poor prognostic factor, and progressive or relapsed disease in the CNS is associated with even worse outcomes. We report 3 boys aged 4, 7, and 12 years treated under the French Société Française d'Oncologie Pédiatrique LMB 89/96 protocols who presented, respectively, with CNS-/bone marrow+ stage-IV BL; CNS+ stage-IV BL; and stage-I BL. Each experienced an isolated CNS relapse, which was treated with CNS-directed salvage chemotherapy. All 3 are alive after 11 years of median follow-up, indicating that this chemotherapy regimen can be curative in pediatric BL with isolated CNS relapse.
Authors:
Frederic Baleydier; Corinne Pondarre; Marie-Pierre Pages; Valerie Mialou; Kamila Kebaili; Jean-Pierre Pracros; Yves Bertrand
Related Documents :
15891195 - Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia ...
12060115 - Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on the uni...
6429875 - A prospective, randomized study of adjuvant parenteral nutrition in the treatment of sa...
18074105 - Continuous intrathecal treatment with methotrexate via subcutaneous port: implication f...
2421345 - Treatment alternatives in advanced testicular cancer.
16813885 - Long-term followup of a randomized study of locally advanced prostate cancer treated wi...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  30     ISSN:  1536-3678     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2009-01-09     Completed Date:  2009-02-03     Revised Date:  2011-10-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  972-5     Citation Subset:  IM    
Affiliation:
Pediatric Immunology and Hematology Department, Institut d'Hématologie et Oncologie Pédiatrique, France. fbaleydier@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Burkitt Lymphoma / drug therapy*,  pathology
Central Nervous System Neoplasms / drug therapy*,  pathology
Child
Child, Preschool
Cyclophosphamide / therapeutic use
Cytarabine / therapeutic use
Humans
Magnetic Resonance Imaging
Male
Methotrexate / therapeutic use
Neoplasm Recurrence, Local / drug therapy*,  pathology
Remission Induction
Salvage Therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
147-94-4/Cytarabine; 50-18-0/Cyclophosphamide; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fibrolamellar hepatocellular carcinoma in an infant and literature review.
Next Document:  Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature.